Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Viruses --- Cancer --- Cancer --- Viruses --- Oncolytic Virotherapy. --- Therapeutic use --- Treatment --- Treatment. --- Therapeutic use. --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Viruses --- Cancer --- Oncolytic Virotherapy. --- Therapeutic use --- Treatment --- Treatment. --- Therapeutic use. --- Oncology. Neoplasms --- oncolytic virology --- cancer --- oncolytic viruses --- oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

After our successful first Special Issue about bladder cancer, we proceeded with the second issue. Again, many international scientists submitted their newest research results in that extremely interesting field and followed our call for submissions. It is not only the collection and combination of old and new markers that could develop new possibilities, but also the focus on different classifications and sub-classifications that will unveil new ways in diagnostic and therapeutic approaches. It seems that the two established diagnostic tools will still play an important role, but new markers and diagnostics tools will present more detailed and more differentiated possibilities in the treatment of urinary bladder cancer. This second Special Issue is full of scientific results that could provide new ways to help patients with instruments for early diagnostics and with predictive and prognostic markers on their way to finding new and personalized strategies for therapy. The editors thank all of the submitting authors for their efforts and time spent on each manuscript. We hope that this Special Issue will prove useful to research work in bladder cancer in the future. We hope that many talented researchers will use multiple forms of art to improve their professional successes and to ameliorate diagnostics and therapy in bladder cancer.

Medicine --- Metallothionein --- urothelium --- urothelial cancer --- cadmium exposure --- zinc transporter --- bladder --- TAGLN --- F-actin --- PTEN --- p53 --- tumorigenesis --- proliferation --- invasion --- TERT promoter mutations --- FGFR3 --- non muscle invasive bladder cancer --- BCG therapy --- bladder cancer --- JAK-STAT pathway --- combination therapy --- oncolytic adenovirus --- virotherapy --- STAT3/5 inhibitor --- JAK inhibitor --- XVir-N-31 --- bladder cancer detection --- urinary biomarkers --- DNA methylation --- ECRG4 --- ITIH5 --- biomarker --- cancer --- grade --- metabolomics --- MS --- NMR --- biomarkers --- tumor markers --- prognosis --- heparanase --- syndecan-1 --- heparan sulfate proteoglycans (HSPGs) --- urothelial carcinoma --- miRNA --- quantitative PCR --- tumor marker --- voided urine cytology --- KDM7A --- histone demethylase --- TC-E 5002 --- androgen receptor --- drug resistance --- non-invasive detection --- telomerase --- somatic mutations --- TERT promoter region --- muscle-invasive bladder cancer --- chemotherapy --- immunotherapy --- personalized medicine --- predictive biomarker --- survivin --- BIRC5 --- macrophage --- KRT20 --- ERBB2 --- MIBC --- prediction --- RT-qPCR --- adjuvant chemotherapy --- survival --- Metallothionein --- urothelium --- urothelial cancer --- cadmium exposure --- zinc transporter --- bladder --- TAGLN --- F-actin --- PTEN --- p53 --- tumorigenesis --- proliferation --- invasion --- TERT promoter mutations --- FGFR3 --- non muscle invasive bladder cancer --- BCG therapy --- bladder cancer --- JAK-STAT pathway --- combination therapy --- oncolytic adenovirus --- virotherapy --- STAT3/5 inhibitor --- JAK inhibitor --- XVir-N-31 --- bladder cancer detection --- urinary biomarkers --- DNA methylation --- ECRG4 --- ITIH5 --- biomarker --- cancer --- grade --- metabolomics --- MS --- NMR --- biomarkers --- tumor markers --- prognosis --- heparanase --- syndecan-1 --- heparan sulfate proteoglycans (HSPGs) --- urothelial carcinoma --- miRNA --- quantitative PCR --- tumor marker --- voided urine cytology --- KDM7A --- histone demethylase --- TC-E 5002 --- androgen receptor --- drug resistance --- non-invasive detection --- telomerase --- somatic mutations --- TERT promoter region --- muscle-invasive bladder cancer --- chemotherapy --- immunotherapy --- personalized medicine --- predictive biomarker --- survivin --- BIRC5 --- macrophage --- KRT20 --- ERBB2 --- MIBC --- prediction --- RT-qPCR --- adjuvant chemotherapy --- survival

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This open access book deals with a rich variety of taxis-type cross-diffusive equations. Particularly, it intends to show the key role played by quasi-energy inequality in the derivation of some necessary a priori estimates. This book addresses applied mathematics and all researchers interested in mathematical development of reaction-diffusion theory and its application and can be a basis for a graduate course in applied mathematics.

Boundary value problems. --- Chemotaxis --- Navier-Stokes equations. --- Mathematical models. --- Equations, Navier-Stokes --- Differential equations, Partial --- Fluid dynamics --- Viscous flow --- Chemiotaxis --- Chemotropism --- Biochemistry --- Growth --- Taxes (Biology) --- Boundary conditions (Differential equations) --- Differential equations --- Functions of complex variables --- Mathematical physics --- Initial value problems --- Problemes de contorn --- Quimiotaxi --- Models matemàtics --- Equacions de Navier-Stokes --- Navier-Stokes (Equacions) --- Dinàmica de fluids --- Equacions en derivades parcials --- Models (Matemàtica) --- Models experimentals --- Models teòrics --- Mètodes de simulació --- Anàlisi de sistemes --- Mètode de Montecarlo --- Modelització multiescala --- Models economètrics --- Models lineals (Estadística) --- Models multinivell (Estadística) --- Models no lineals (Estadística) --- Programació (Ordinadors) --- Simulació per ordinador --- Teoria de màquines --- Models biològics --- Bioquímica --- Creixement --- Problemes de valor límit --- Equacions diferencials --- Física matemàtica --- Funcions de variables complexes --- Dispersió (Matemàtica) --- Equacions de Von Kármán --- Problema de Dirichlet --- Problema de Neumann --- Problemes de Riemann-Hilbert --- Problemes de valor inicial --- Reaction-Diffusion --- Haptotaxis --- Navier-Stokes --- Cancer invasion --- Coral fertilization --- Sensity-suppressed motility --- Oncolytic virotherapy --- Foraging scrounging interplay

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.

oncolytic viruses --- melanoma --- immunotherapy --- checkpoint inhibitors --- combinatory therapy --- reovirus --- oncolytic virus --- adenovirus --- oncolytic --- virotherapy --- targeting --- immunogenic cell death --- αvβ6 integrin --- oncolytic adenovirus --- cancer immunotherapy --- multi-stage --- immunostimulatory --- arming --- HSV-1 --- clinical trials --- newcastle disease virus --- NDV --- cancer --- immune checkpoint inhibitor --- PD-1 --- PD-L1 --- CTLA-4 --- type I interferon --- herpes simplex virus --- retargeted virus --- tropism retargeting --- tumor --- checkpoint inhibitor --- vaccination --- antigen-agnostic vaccination --- HER2 --- parvovirus --- tumor microenvironment --- combination therapy --- glioblastoma --- pancreatic cancer --- colorectal cancer --- measles virus --- vector engineering --- immune checkpoint blockade --- antitumor immune response --- delivery --- genetic modification --- biomarkers --- personalized oncolyticvirotherapy --- class I HLA --- immunosurveillance --- immunoediting --- oncogenic signaling --- RAS --- DNA methyltransferase inhibitor (DNMTi) --- viral mimicry --- epigenetic silencing --- adoptive T cell therapy --- CAR T cell --- pancreatic ductal adenocarcinoma --- vesicular stomatitis virus --- small molecule --- cancer immune therapy --- cancer therapy --- n/a